Targets and treatments in primary CNS lymphoma

References

• Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410–2418. doi:10.1200/JCO.2017.72.7602
   PubMed Web of Science ®Google Scholar
• Mendez JS, Ostrom QT, Gittleman H, et al. The elderly left behind-changes in survival trends of primary Central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;20(5):687–694. doi:10.1093/neuonc/nox187
   PubMed Web of Science ®Google Scholar
• Raval V, Binkley E, Aronow ME, et al. Primary central nervous system lymphoma: inter‐compartmental progression. EJHaem. 2022;3(2):362–370. doi:10.1002/jha2.303
   PubMedGoogle Scholar
• Ferreri AJM, Calimeri T, Cwynarski K, et al. Primary central nervous system lymphoma. Nat Rev Dis Primers. 2023;9(1):29. doi:10.1038/s41572-023-00439-0
   PubMedGoogle Scholar
• Shiels MS, Pfeiffer RM, Besson C, et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol. 2016;174(3):417–424. doi:10.1111/bjh.14073
   PubMed Web of Science ®Google Scholar
• Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000;92(2):261–266. doi:10.3171/jns.2000.92.2.0261
   PubMed Web of Science ®Google Scholar
• Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood. 2022;140(9):971–979. doi:10.1182/blood.2020008377
   PubMed Web of Science ®Google Scholar
• Barajas RF, Politi LS, Anzalone N, et al. Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol. 2021;23(7):1056–1071. doi:10.1093/neuonc/noab020
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Blay J-Y, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21(2):266–272. doi:10.1200/JCO.2003.09.139
   PubMed Web of Science ®Google Scholar
• Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24(36):5711–5715. doi:10.1200/JCO.2006.08.2941
   PubMed Web of Science ®Google Scholar
• Grommes C, Rubenstein JL, DeAngelis LM, et al. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol. 2019;21(3):296–305. doi:10.1093/neuonc/noy192
   PubMed Web of Science ®Google Scholar
• Calimeri T, Steffanoni S, Gagliardi F, et al. How we treat primary central nervous system lymphoma. ESMO Open. 2021;6(4):100213. doi:10.1016/j.esmoop.2021.100213
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Central Nervous System Cancers V1; 2023. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.
   Google Scholar
• Hoang-Xuan K, Deckert M, Ferreri AJM, et al. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro Oncol. 2023;25(1):37–53. doi:10.1093/neuonc/noac196
   PubMed Web of Science ®Google Scholar
• Reni M, Ferreri AJ, Garancini MP, et al. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol. 1997;8(3):227–234. doi:10.1023/a:1008201717089
   PubMed Web of Science ®Google Scholar
• Bellinzona M, Roser F, Ostertag H, et al. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol. 2005;31(1):100–105. doi:10.1016/j.ejso.2004.10.002
   PubMed Web of Science ®Google Scholar
• Tao K, Wang X, Tian X. Relapsed primary Central nervous system lymphoma: current advances. Front Oncol. 2021;11:649789. doi:10.3389/fonc.2021.649789
   PubMed Web of Science ®Google Scholar
• Nayak L, Hedvat C, Rosenblum MK, et al. Late relapse in primary central nervous system lymphoma: clonal persistence. Neuro Oncol. 2011;13(5):525–529. doi:10.1093/neuonc/nor014
   PubMed Web of Science ®Google Scholar
• Houillier C, Soussain C, Ghesquières H, et al. Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology. 2020;94(10):e1027–e1039. doi:10.1212/WNL.0000000000008900
   PubMed Web of Science ®Google Scholar
• Langner-Lemercier S, Houillier C, Soussain C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 2016;18(9):1297–1303. doi:10.1093/neuonc/now033
   PubMed Web of Science ®Google Scholar
• Mo F, Pellerino A, Soffietti R, et al. Blood-brain barrier in brain tumors: biology and clinical relevance. Int J Mol Sci. 2021;22(23):12654. doi:10.3390/ijms222312654
   PubMed Web of Science ®Google Scholar
• Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007;25(16):2295–2305. doi:10.1200/JCO.2006.09.9861
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Calimeri T, Ponzoni M, et al. Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. Blood Adv. 2020;4(15):3648–3658. doi:10.1182/bloodadvances.2020002270
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101(2):466–468. doi:10.1182/blood-2002-06-1636
   PubMed Web of Science ®Google Scholar
• Yuan Y, Ding T, Wang S, et al. Current and emerging therapies for primary central nervous system lymphoma. Biomark Res. 2021;9(1):32. doi:10.1186/s40364-021-00282-z
   PubMed Web of Science ®Google Scholar
• Alcantara M, Fuentealba J, Soussain C. Emerging landscape of immunotherapy for primary central nervous system lymphoma. Cancers (Basel). 2021;13(20):5061. doi:10.3390/cancers13205061
   PubMed Web of Science ®Google Scholar
• Wang W, He H, Marín-Ramos NI, et al. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro Oncol. 2021;23(10):1656–1667. doi:10.1093/neuonc/noab041
   PubMed Web of Science ®Google Scholar
• de Lange ECM. Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn. 2013;40(3):315–326. doi:10.1007/s10928-013-9301-9
   PubMed Web of Science ®Google Scholar
• Ferreri AJM. How I treat primary CNS lymphoma. Blood. 2011;118(3):510–522. doi:10.1182/blood-2011-03-321349
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Calimeri T, Conte GM, et al. R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma. Blood. 2019;134(3):252–262. doi:10.1182/blood.2019000633
   PubMed Web of Science ®Google Scholar
• Iorio-Morin C, Gahide G, Morin C, et al. Management of primary central nervous system lymphoma using intra-arterial chemotherapy with osmotic blood-brain barrier disruption: retrospective analysis of the sherbrooke cohort. Front Oncol. 2020;10:543648. doi:10.3389/fonc.2020.543648
   PubMed Web of Science ®Google Scholar
• Doolittle ND, Muldoon LL, Culp AY, et al. Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances. Adv Pharmacol. 2014;71:203–243. doi:10.1016/bs.apha.2014.06.002
   PubMedGoogle Scholar
• Gandhi K, Barzegar-Fallah A, Banstola A, et al. Ultrasound-mediated blood–brain barrier disruption for drug delivery: a systematic review of protocols, efficacy, and safety outcomes from preclinical and clinical studies. Pharmaceutics. 2022;14(4):833. doi:10.3390/pharmaceutics14040833
   PubMed Web of Science ®Google Scholar
• Rezai AR, D'Haese P-F, Finomore V, et al. Ultrasound blood-brain barrier opening and aducanumab in Alzheimer’s disease. N Engl J Med. 2024;390(1):55–62. doi:10.1056/NEJMoa2308719
   PubMed Web of Science ®Google Scholar
• Schönthal AH, Peereboom DM, Wagle N, et al. Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. Neurooncol Adv. 2021;3(1):vdab005.
   PubMedGoogle Scholar
• Takeuchi H, Matsuda K, Kitai R, et al. Angiogenesis in primary central nervous system lymphoma (PCNSL). J Neurooncol. 2007;84(2):141–145. doi:10.1007/s11060-007-9363-x
   PubMed Web of Science ®Google Scholar
• Iwamoto FM, Schwartz J, Pandit-Taskar N, et al. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer. 2007;110(11):2528–2534. doi:10.1002/cncr.23077
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Gupta NK, Mannis GN, et al. How I treat CNS lymphomas. Blood. 2013;122(14):2318–2330. doi:10.1182/blood-2013-06-453084
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Li J, Chen L, et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013;121(5):745–751. doi:10.1182/blood-2012-07-440974
   PubMed Web of Science ®Google Scholar
• Hernández-Verdin I, Kirasic E, Wienand K, et al. Molecular and clinical diversity in primary central nervous system lymphoma. Ann Oncol. 2023;34(2):186–199. doi:10.1016/j.annonc.2022.11.002
   PubMed Web of Science ®Google Scholar
• Camilleri-Broët S, Crinière E, Broët P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107(1):190–196. doi:10.1182/blood-2005-03-1024
   PubMed Web of Science ®Google Scholar
• Radke J, Ishaque N, Koll R, et al. The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat Commun. 2022;13(1):2558. doi:10.1038/s41467-022-30050-y
   PubMed Web of Science ®Google Scholar
• Bromberg JEC, Issa S, Bakunina K, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019;20(2):216–228. doi:10.1016/S1470-2045(18)30747-2
   PubMed Web of Science ®Google Scholar
• Schaff LR, Grommes C. Update on novel therapeutics for primary CNS lymphoma. Cancers (Basel). 2021;13(21):5372. doi:10.3390/cancers13215372
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Cwynarski K, Pulczynski E, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022;36(7):1870–1878. doi:10.1038/s41375-022-01582-5
   PubMed Web of Science ®Google Scholar
• Schmitt AM, Herbrand AK, Fox CP, et al. Rituximab in primary central nervous system lymphoma-a systematic review and meta-analysis. Hematol Oncol. 2019;37(5):548–557. doi:10.1002/hon.2666
   PubMed Web of Science ®Google Scholar
• Chapuy B, Roemer MGM, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–881. doi:10.1182/blood-2015-10-673236
   PubMed Web of Science ®Google Scholar
• Bruno A, Boisselier B, Labreche K, et al. Mutational analysis of primary central nervous system lymphoma. Oncotarget. 2014;5(13):5065–5075. doi:10.18632/oncotarget.2080
   PubMed Web of Science ®Google Scholar
• Vater I, Montesinos-Rongen M, Schlesner M, et al. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia. 2015;29(3):677–685. doi:10.1038/leu.2014.264
   PubMed Web of Science ®Google Scholar
• Nakamura T, Tateishi K, Niwa T, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2016;42(3):279–290. doi:10.1111/nan.12259
   PubMed Web of Science ®Google Scholar
• Braggio E, Van Wier S, Ojha J, et al. Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res. 2015;21(17):3986–3994. doi:10.1158/1078-0432.CCR-14-2116
   PubMed Web of Science ®Google Scholar
• Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018–1029. doi:10.1158/2159-8290.CD-17-0613
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833–843.e5. doi:10.1016/j.ccell.2017.04.012
   PubMed Web of Science ®Google Scholar
• Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II “proof-of-concept” iLOC study by the lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121–130. doi:10.1016/j.ejca.2019.05.024
   PubMed Web of Science ®Google Scholar
• Asai K, Narita Y, Nagane M, et al. Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. J Clin Oncol. 2023;41(16 Suppl.):7548–7548. doi:10.1200/JCO.2023.41.16_suppl.7548
   Google Scholar
• Profitós-Pelejà N, Santos JC, Marín-Niebla A, et al. Regulation of B-cell receptor signaling and its therapeutic relevance in aggressive B-cell lymphomas. Cancers (Basel). 2022;14(4):860. doi:10.3390/cancers14040860
   PubMed Web of Science ®Google Scholar
• Narita Y, Nagane M, Mishima K, et al. Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol. 2021;23(1):122–133. doi:10.1093/neuonc/noaa145
   PubMed Web of Science ®Google Scholar
• Motshwene PG, Moncrieffe MC, Grossmann JG, et al. An oligomeric signaling platform formed by the toll-like receptor signal transducers MyD88 and IRAK-4. J Biol Chem. 2009;284(37):25404–25411. doi:10.1074/jbc.M109.022392
   PubMed Web of Science ®Google Scholar
• Smith MA, Choudhary GS, Pellagatti A, et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat Cell Biol. 2019;21(5):640–650. doi:10.1038/s41556-019-0314-5
   PubMed Web of Science ®Google Scholar
• Gummadi VR, Boruah A, Ainan BR, et al. Discovery of CA-4948, an orally bioavailable IRAK4 inhibitor for treatment of hematologic malignancies. ACS Med Chem Lett. 2020;11(12):2374–2381. doi:10.1021/acsmedchemlett.0c00255
   PubMed Web of Science ®Google Scholar
• Von Roemeling CA, Doonan BP, Klippel K, et al. Oral IRAK-4 inhibitor CA-4948 is blood-brain barrier penetrant and has single-agent activity against CNS lymphoma and melanoma brain metastases. Clin Cancer Res. 2023;29(9):1751–1762. doi:10.1158/1078-0432.CCR-22-1682
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Calimeri T, Lopedote P, et al. Clinical relevance of MYD88 L265P mutation and interleukin-10 level in cerebrospinal fluid of patients with both newly diagnosed and relapsed primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2019;134(Suppl. 1):4114–4114. doi:10.1182/blood-2019-128298
   Google Scholar
• Watanabe J, Natsumeda M, Okada M, et al. High detection rate of MYD88 mutations in cerebrospinal fluid from patients with CNS lymphomas. J Clin Oncol Precis Oncol. 2019;3:1–13. doi:10.1200/PO.18.00308
   PubMed Web of Science ®Google Scholar
• Von Roemeling C, Iqbal M, Doonan B, et al. P1298: the IRAK-4 inhibitor emavusertib (CA-4948) for the treatment of primary CNS lymphoma. Hemasphere. 2022;6(Suppl).:1183–1184. doi:10.1097/01.HS9.0000848056.06353.f1
   Google Scholar
• Guidetti F, Arribas AJ, Sartori G, et al. Targeting IRAK4 with emavusertib in lymphoma models with secondary resistance to PI3K and BTK inhibitors. J Clin Med. 2023;12(2):399. doi:10.3390/jcm12020399
   PubMed Web of Science ®Google Scholar
• Guidetti F, Arribas AJ, Cannas E, et al. The IRAK4 inhibitor emavusertib (CA-4948) synergizes with second generation BTK inhibitors acalabrutinib and zanubrutinib in MYD88-L265P mutated lymphoma cell lines. Mol Cancer Ther. 2023;22(12 Suppl.):C139. doi:10.1158/1535-7163.TARG-23-C139
   Google Scholar
• Grommes C, Tun H, Rosenthal AC, et al. Takeaim lymphoma: an open-label, dose escalation and expansion trial of emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies. Blood. 2023;142(Suppl. 1):4497–4497. doi:10.1182/blood-2023-189746
   Google Scholar
• Zhai Y, Zhou X, Wang X. Novel insights into the biomarkers and therapies for primary central nervous system lymphoma. Ther Adv Med Oncol. 2022;14:17588359221093745. doi:10.1177/17588359221093745
   Web of Science ®Google Scholar
• Hoang-Xuan K, Houot R, Soussain C, et al. First results of the AcSé pembrolizumab phase II in the primary CNS lymphoma (PCNSL) cohort. Blood. 2020;136(Suppl. 1):15–16. doi:10.1182/blood-2020-141773
   Google Scholar
• Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the leukemia and lymphoma molecular profiling project. Blood. 2004;103(11):4251–4258. doi:10.1182/blood-2003-07-2365
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3073. doi:10.1182/blood-2017-01-764209
   PubMed Web of Science ®Google Scholar
• Wu X, Zhang X, Xun R, et al. Efficacy and safety of axicabtagene ciloleucel and tisagenlecleucel administration in lymphoma patients with secondary CNS involvement: a systematic review. Front Immunol. 2021;12:693200. doi:10.3389/fimmu.2021.693200
   PubMed Web of Science ®Google Scholar
• Frigault MJ, Dietrich J, Gallagher K, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022;139(15):2306–2315. doi:10.1182/blood.2021014738
   PubMed Web of Science ®Google Scholar
• Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860–866. doi:10.1182/blood.2019001694
   PubMed Web of Science ®Google Scholar
• Alcantara M, Houillier C, Blonski M, et al. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. Blood. 2022;139(5):792–796. doi:10.1182/blood.2021012932
   PubMed Web of Science ®Google Scholar
• Siddiqi T, Wang X, Blanchard MS, et al. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 2021;5(20):4059–4063. doi:10.1182/bloodadvances.2020004106
   PubMed Web of Science ®Google Scholar
• Plaks V, Rossi JM, Chou J, et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood. 2021;138(12):1081–1085. doi:10.1182/blood.2021010930
   PubMed Web of Science ®Google Scholar
• Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359–371. doi:10.1038/s41571-023-00754-1
   PubMed Web of Science ®Google Scholar
• Tu S, Zhou X, Guo Z, et al. CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma. Front Oncol. 2019;9:1350. doi:10.3389/fonc.2019.01350
   PubMed Web of Science ®Google Scholar
• Li Z, Qiu Y, Personett D, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013;8(8):e71754. doi:10.1371/journal.pone.0071754
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Geng H, Fraser EJ, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018;2(13):1595–1607. doi:10.1182/bloodadvances.2017014845
   PubMed Web of Science ®Google Scholar
• Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective “proof of concept” phase II study of the French Oculo-Cerebral lymphoma (LOC) network and the lymphoma study association (LYSA). Ann Oncol. 2019;30(4):621–628. doi:10.1093/annonc/mdz032
   PubMed Web of Science ®Google Scholar
• Tun HW, Johnston PB, DeAngelis LM, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018;132(21):2240–2248. doi:10.1182/blood-2018-02-835496
   PubMed Web of Science ®Google Scholar
• Korfel A, Schlegel U, Herrlinger U, et al. Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma. J Clin Oncol. 2016;34(15):1757–1763. doi:10.1200/JCO.2015.64.9897
   PubMedGoogle Scholar
• Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23(18):3151–3171. doi:10.1038/sj.onc.1207542
   PubMed Web of Science ®Google Scholar
• Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin’s lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol. 2010;28(31):4740–4746. doi:10.1200/JCO.2010.29.2813
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(23):3822–3829. doi:10.1200/JCO.2008.20.7977
   PubMed Web of Science ®Google Scholar
• Grommes C, Pentsova E, Nolan C, et al. Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Ann Oncol. 2016;27:vi106. doi:10.1093/annonc/mdw367.13
   Web of Science ®Google Scholar